April 09, 2005

Cognitive Enhancement Drug News

Cognitive Enhancement Drug News

From a Company press release by Saegis Pharmaceuticals:

HALF MOON BAY, Calif., March 29 /PRNewswire/ --

Saegis Pharmaceuticals, Inc., a biopharmaceutical company focused on developing medicines that protect and enhance memory and cognition, today announced the successful completion of a Phase I clinical study of SGS518. SGS518 is being developed as a treatment for Cognitive Impairment Associated with Schizophrenia (CIAS).

The primary objective of the Phase I study was to evaluate safety and tolerability, as well as the pharmacokinetics, of SGS518. The placebo-controlled, blinded study was conducted among healthy volunteers in two cohorts, including a dose-ranging arm, followed by a multi-dose study. The conclusion of both arms of the Phase I study found SGS518 to be safe and well tolerated.

"This was a first-in-man study with a new chemical entity and we are very pleased with the positive safety data obtained for SGS518. These data provide valuable direction for our Phase II clinical program," said Rodney Pearlman, Ph.D., President and CEO of Saegis. "Currently, there are few, if any, therapies available for individuals suffering from Cognitive Impairment Associated with Schizophrenia and our intention is to evaluate the efficacy of SGS518 in this patient population. It is hoped that an effective treatment for the cognitive impairment in schizophrenia will help patients lead more normal and productive lives."

More information see: Saegis Pharmaceuticals

More information on new drugs being worked on for schizophrenia


Post a comment

Please enter this code to enable your comment -
Remember Me?
(you may use HTML tags for style)
* indicates required